Background-Peak oxygen consumption (VO 2 ) is routinely assessed in patients with heart failure undergoing cardiopulmonary exercise testing. The purpose of the present investigation was to determine the prognostic ability of several established peak VO 2 prediction equations in a large heart failure cohort. Methods and Results-One thousand one hundred sixty-five subjects (70% males; age, 57.0Ϯ13.8 years; ischemic etiology, 43%) diagnosed with heart failure underwent cardiopulmonary exercise testing. Percent-predicted peak VO 2 was calculated according to normative values proposed by Wasserman and Hansen (equation), Jones et al (equation), the Cooper Clinic (below low fitness threshold), a Veteran's Administration male referral data set (4 equations), and the St James Take Heart Project for women (equation). The prognostic significance of percent-predicted VO 2 values derived from the 2 latter, sex-specific equations were assessed collectively. There were 179 major cardiac events (117 deaths, 44 heart transplantations, and 18 left ventricular assist device implantations) during the 2-year tracking period (annual event rate, 10%). Measured peak VO 2 and all percent-predicted peak VO 2 calculations were significant univariate predictors of adverse events (
P eak oxygen consumption (VO
) is a clinically accepted and important variable in the prognostic evaluation of patients with heart failure (HF) undergoing cardiopulmonary exercise testing (CPX). 1 The actual value of peak VO 2 , typically expressed relative to body weight, is the most common approach to reporting aerobic capacity in apparently healthy individuals and different patient populations, including HF. 2 Reporting peak VO 2 as a percent-predicted value has also been advocated. Moreover, a number of different approaches to estimating normal aerobic capacity are readily available. [3] [4] [5] [6] [7] [8] [9] These prediction equations have used various independent variables such as height, weight, and mode of exercise but the inclusion of age and consideration of sex is a shared commonality.
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The body of evidence demonstrating the prognostic utility of the actual peak VO 2 value is robust; collectively, these investigations have included thousands of patients and hundreds of adverse events, consistently demonstrating the ability of this CPX variable to identify those patients with HF at increased risk for poor outcomes. 10 A limited number of investigations have also examined the prognostic value of percent-predicted peak VO 2 in patients with HF with mixed results. For example, using 2 different prediction equations, Aaronson and Mancini 11 found neither percent-predicted peak VO 2 value was a superior prognostic marker compared with the actual value in 272 patients with HF. However, using one equation, Stelken et al 12 reported percent-predicted peak VO 2 was superior to the actual value in predicting mortality in a separate group of 181 patients with HF.
We are unaware of any investigation that has simultaneously compared the prognostic utility of the most commonly used peak VO 2 prediction equations with each other and the actual aerobic capacity value in a large HF cohort undergoing CPX within the past 10 years. Moreover, a prognostic comparison of percent-predicted VO 2 values to other important CPX measures, such as ventilatory efficiency, has not been performed. The purpose of the present investigation was to address these issues in an effort to determine the clinical relevance of expressing peak VO 2 relative to a normative value in patients with HF.
Methods
This study was a multicenter analysis including patients with HF from the CPX laboratories at San Paolo Hospital (Milan, Italy), Wake Forest University Baptist Medical Center (Winston-Salem, NC), LeBauer Cardiovascular Research Foundation (Greensboro, NC) Veteran's Administration (VA) Palo Alto Health Care System (Palo Alto, Calif), and Virginia Commonwealth University (Richmond, Va). A total of 1165 patients with chronic HF were included. Inclusion criteria consisted of a diagnosis of HF 13 and evidence of left ventricular dysfunction by 2D echocardiography obtained within 1 month of data collection. All subjects completed a written informed consent and institutional review board approval was obtained at each institution. The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
CPX Procedure and Data Collection
Symptom-limited CPX was performed on all subjects and pharmacological therapy was maintained during exercise testing. Conservative ramping protocols were used at all centers. Ventilatory expired gas analysis was performed using a metabolic cart at all 5 centers (Medgraphics CPX-D and Ultima, Minneapolis, Minn; Sensormedics Vmax29, Yorba Linda, Calif; or Parvomedics TrueOne 2400, Sandy, Utah). Before each test, the equipment was calibrated in standard fashion using reference gases and a 3-L syringe. Standard 12-lead electrocardiograms were monitored throughout exercise; blood pressure was measured using a standard cuff sphygmomanometer. Heart rate at rest and maximal exercise were obtained from the ECG. Heart rate recovery at 1 minute was the difference between heart rate at peak exercise and 1-minute post. All subjects performed an active cool-down, at the initial workload of the exercise protocol, for at least 1 minute after the cessation of exercise. Minute ventilation (VE), oxygen uptake (VO 2 ), carbon dioxide output (VCO 2 ), and end-tidal carbon dioxide production (P ET CO 2 ) were acquired breath-by-breath, and averaged over 10-second intervals. Resting P ET CO 2 was expressed as a 2-minute averaged value in millimeter of mercury. Peak VO 2 and peak respiratory exchange ratio were expressed as the highest 10-second averaged samples obtained during the exercise test. VE and VCO 2 values, acquired from the initiation of exercise to peak, were input into spreadsheet software (Microsoft Excel, Microsoft Corp, Bellevue, Wash) to calculate the VE/VCO 2 slope via least squares linear regression (yϭmxϩb, mϭslope). 14, 15 The oxygen uptake efficiency slope was also determined via least squares linear regression (VO 2 ϭa log 10 VEϩb) 16 by spreadsheet software (Microsoft Excel, Seattle, Wash) using all of the exercise data. Percent-predicted peak VO 2 was calculated according to normative values proposed by Wasserman and Hansen 4, 5 (1 of 6 equations according to sex and bodyweight), Jones et al (equation), 3 the Cooper Clinic (below low fitness threshold), 8, 9 a VA male referral data set (4 equations; A to D), 6 and the St James Take Heart Project for women (equation). 7 The prognostic significance of percent-predicted VO 2 values derived from the 2 latter, sex-specific prediction equations were assessed collectively (VA A to D/St James).
End Points
Subjects were followed for major cardiac events (mortality, left ventricular assist device implantation, heart transplantation) via hospital and outpatient medical chart review for a maximum of 2 years at all centers. Any death with a cardiac-related discharge diagnosis was considered an event. Clinicians conducting the exercise test were not involved in decisions regarding cause of death or heart transplant/left ventricular assist device implantation.
Statistical Analysis
All continuous data are reported as meanϮSD. Unpaired t testing assessed differences in continuous baseline and CPX variables between those subjects experienceing an event and those who were event free. 2 analysis assessed differences in the distributions of HF etiology, gender, race, and pharmacological management between these groups. One-way ANOVA compared differences in the percent-predicted peak VO 2 values according to the various equations in the overall group. A mixed-model 2-way ANOVA assessed differences between percent-predicted peak VO 2 values (within subject factors) according to adverse event status (between subject factors). When a significant difference between percent-predicted peak VO 2 values was detected, post hoc analysis was performed by multiple paired testing with a Bonferroni correction (PϽ0.007 [0.05/7]). Receiver operating characteristic (ROC) curves were constructed for the prognostic classification schemes of all percentpredicted peak VO 2 values. A z test was used to assess for significance of differences among areas under the ROC curve for the prognostic models. 17 Univariate Cox regression analysis assessed the prognostic value of percent-predicted peak VO 2 calculations for cardiac mortality alone and in subgroups according to sex, mode of exercise (treadmill versus lower extremity ergometer), peak respiratory exchange ratio (Ͻversus Ն1.05), and age (Ͻversus Ն50 years old). Separate multivariate Cox regression analyses (forward stepwise method, entry, and removal values 0.10 and 0.05, respectively) then assessed the combined prognostic value of the VE/VCO 2 slope and each expression of peak VO 2 (actual and percent-predicted values). Multivariate Cox regression analysis was also used to assess the prognostic value of the VE/VCO 2 slope, peak VO 2 expressions, and an expanded list of baseline variables including age, HF etiology, left ventricular ejection fraction, and New York Heart Association (NYHA) class. For the peak VO 2 expression demonstrating the highest prognostic value in the expanded multivariate Cox regression, Kaplan-Meier analysis was performed including all variables retained in that particular regression. The log-rank test determined statistical significance of the Kaplan-Meier analysis. With the exception of post hoc testing for the mixed-model, 2-way ANOVA, all statistical tests with a probability value Ͻ0.05 were considered significant.
Results
There were 179 major cardiac events (117 deaths, 44 heart transplantations, and 18 left ventricular assist device implantations) during the 2-year tracking period (annual event rate, 10%). Baseline characteristics for the overall group as well as subgroups according to adverse event status are listed in Table 1 . The percentages of subjects with an ischemic HF etiology and prescribed a diuretic were significantly higher in subjects experienceing a major cardiac event. In addition, mean NYHA class was significantly higher whereas left ventricular ejection fraction was significantly lower in the major cardiac event subgroup.
CPX results for the overall group and subgroups according to adverse event status are listed in Table 2 . In the overall group, all percent-predicted peak VO 2 values were signifi- *Hazard ratios generated from univariate Cox regression using optimal threshold value. †Significantly greater than VA-C/St James (PϽ0.01) and VA-D/St. James (PϽ0.05). ‡Significantly greater than VA-C/St James (PϽ0.01). §Significantly greater than VA-C/St James (PϽ0.05).
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cantly different, with the exception of values derived from the VA-B/St James and Cooper clinic equations. Aside from mode of exercise characteristics and peak respiratory exchange ratio, all variables of interest were significantly different according to adverse event status. Peak VO 2 , maximal heart rate, and all percent-predicted peak VO 2 calculations were significantly lower whereas the VE/VCO 2 slope was significantly higher in subjects experienceing a major cardiac event. Moreover, all percent-predicted peak VO 2 calculations were significantly different between those with and without a major event. Resting P ET CO 2 , the oxygen uptake efficiency slope, and heart rate recovery at 1 minute data were available in 737 (major events, 120), 452 (major events, 62), and 612 (major events, 82) subjects, respectively. For these subgroups, resting P ET CO 2 (34.3Ϯ4.5 versus 32.5Ϯ4.5 mm Hg), the oxygen uptake efficiency slope (1.8Ϯ0.9 versus 1.3Ϯ0.6), and heart rate recovery at 1 minute (19.2Ϯ11.8 versus 12.0Ϯ9.6 beats per minute) were all significantly higher (PϽ0.001) in subjects who did not experience a major cardiac event.
ROC curve analysis results for the different peak VO 2 prediction equations is listed in Table Table 4 lists the prognostic value of percent-predicted VO 2 values according to cardiac mortality as the only end point and sex, mode of exercise, exercise effort, and age-based subgroups. The ability of all percent-predicted VO 2 values to predict major adverse events remained statistically significant when cardiac mortality was considered the only end point and in all subgroup analyses.
Multivariate Cox regression analysis including the VE/VCO 2 slope and each expression of aerobic capacity is listed in Table  5 . The VE/VCO 2 slope was the superior predictor of major cardiac events in each analysis whereas measured peak VO 2 and each percent-predicted peak VO 2 calculation added predictive value and were thus retained in the regression. The residual 2 value was greatest for the percent-predicted peak VO 2 value derived from the Wasserman/Hansen equation.
Two expanded multivariate Cox regression analyses that included the VE/VCO 2 slope, either measured peak VO 2 or percent-predicted peak VO 2 according the Wasserman/Hansen equation and key baseline characteristics are presented in Table 6 . The VE/VCO 2 slope was again the superior prognostic marker in both assessments. Measured peak VO 2 and percent-predicted peak VO 2 Kaplan-Meier analysis curves are illustrated in the Figure. Dichotomous thresholds of Ͻ or Ն36.0, Ͻ or Ն47%, Յ or Ͼ25%, and I/II versus III/IV were set for the VE/VCO 2 slope, 18 percent-predicted peak VO 2 according to the Wasserman/Hansen equation (determined by ROC curve analysis in the present investigation), left ventricular ejection fraction, 13 and the NYHA class, respectively. Using these thresholds, there was a significant difference in adverse event rates between subgroups according to the number of abnormal characteristics. (1) provide values that are for the most part significantly different from one another, limiting the portability of a given equation to different populations of patients with HF; (2) are all prognostically significant in a large HF cohort from a univariate perspective; (3) are all prognostically significant when only cardiac mortality was considered as an end point; (4) all provide prognostic value in subgroups according to sex, mode of exercise, exercise effort and age; and (5) all provide additional prognostic value in a multivariate model including other clinically established exercise and resting variables. In the prognostic comparison between equations, it seems the Wasserman/Hansen calculations provided better resolution, although differences in areas under the ROC curve were not significantly different compared with most other equations assessed. The potential value of the Wasserman/Hansen equations is more so apparent in the multivariate Cox regression analysis that included the VE/VCO 2 slope and key resting variables (Tables 5 and 6 ). In these analyses, percentpredicted values derived from the Wasserman/Hansen approach possessed the highest univariate 2 value (compared with measured peak VO 2 and other percent-predicted calculations), was retained in the multivariate regression and outperformed both left ventricular ejection fraction and NYHA class. Although measured peak VO 2 and all other percent-predicted calculations were also retained in their respective multivariate Cox regression analyses, their added prognostic value was not as powerful as compared with that derived from inclusion of the Wasserman/Hansen equations. The findings of the present study are consistent with the previous investigation by Stelken et al 12 in that percentpredicted peak VO 2 according to the Wasserman/Hansen equations prognostically outperformed an abbreviated list of other equations and measured peak VO 2 in 181 patients with HF. Similalry, Osada et al 19 found percent-predicted peak VO 2 , again derived from the Wasserman/Hansen equations, prognostically outperformed measured peak VO 2 in 500 patients with HF. Aaronson and Mancini, 11 however, found that the Wasserman/Hansen percent-predicted VO 2 calculations and measured peak VO 2 performed similarly in a HF cohort comprised of 272 patients. An advantage of the present investigation compared to these previous studies is the larger sample size, possibly lending more credence to our findings and supporting the previous investigations by Stelken et al 12 and Osada et al. 19 Previous investigations 12, 19 have solely used a percentpredicted peak VO 2 threshold of 50% in their dichotomous prognostic assessments. Determination of this threshold seems to have been more arbitrary than the optimal sensitivity/specificity determination via ROC curve analysis. Despite differences in determination of the dichotomous threshold used in the current and previous investigations, the cut point was for the most part similar. This concordance of research indicates that patients with a percent-predicted VO 2 value below Ϸ50% have poorer outcomes compared with those surpassing this threshold, although the optimal cut point may slightly deviate from 50% for a given predicted peak VO 2 equation.
There is considerable variation in how presently available prediction equations are defined. Although all equations considered age and sex, the Wasserman/Hansen male/female equations have taken the greatest number of additional factors into consideration, including body weight (underweight/normal weight/overweight), mode of exercise (treadmill/lower extremity ergometer), and sedentary lifestyle. Moreover, the Wasserman/Hansen, Jones, VA-A, and VA-B equations, used peak VO 2 determined by ventilatory expired gas analysis to develop their normative values. The VA-C, VA-D, St James, and Cooper Clinic equations all estimated aerobic capacity from treadmill speed/grade or exercise time. Given the differences in equation development, the improved prognostic utility of the Wasserman/Hansen equations may be the result of their ability to account for more explanatory variables and provide a truer depiction of aerobic capacity for an apparently healthy, but sedentary individual. It should be noted, however, that despite the potential limitations of the other prediction equations assessed in the present investigation, they all provided significant prognostic value both independently and in combination with clinically important variables.
It could be argued that the additional steps required for the Wasserman/Hansen equations are not worth the relatively modest increment gained in prognostic information. However, these equations are easily incorporated into the software packages that operate CPX systems. The percent-predicted peak VO 2 value according to the Wasserman/Hansen equation can, therefore, be automatically generated by manually inputting age, sex, height, weight, and mode of exercise, a procedure which is already commonplace in preparation for a CPX. The ease by which all percent-predicted peak VO 2 calculations are derived by presently available software packages eliminates the need for consideration of a given equations complexity.
There is a wealth of research supporting the prognostic strength of the VE/VCO 2 slope in HF, which commonly outperforms measured peak VO 2 . 18,20 -22 Although the prognostic value of the VE/VCO 2 slope is gaining clinical recognition, peak VO 2 continues to be the sole or primary CPX variable considered in the prognostic assessment of patients with HF undergoing this procedure. The results of the present study indicate measured or percent-predicted peak VO 2 should continue to be considered as a secondary CPX variable, complimenting the insight gained from the VE/VCO 2 slope. Irrespective of which variable provides the highest level of prognostic information, it seems clear from the recent literature that the ability to predict adverse events improves with multivariate modeling that includes CPX variables and key resting measures such as NYHA class and left ventricular ejection fraction. 21 Subjects included in the present investigation were referred for CPX at their respective institution, creating the potential for selection bias. Caution must, therefore, be taken in extrapolating our findings to the population with HF as a whole or to CPX laboratories assessing patients with HF with differing characteristics, such as, for example, younger individuals with a congenital heart defect being considered for transplantation. Moreover, although the overall number of subjects in the present investigation exceeded 1000, the majority were male. Although all percent-predicted VO 2 equations were prognostic in the female subgroup, particular caution should be taken in extrapolating our findings to the female population with HF. Given the heterogeneous nature of this disease process, future investigations should be performed in other HF cohorts to determine whether the prognostic value of percent-predicted peak VO 2 is universally applicable to this chronic disease population. Although peak VO 2 and the VE/VCO 2 slope are well established, other variables, such as resting P ET CO 2 , 23 the oxygen uptake efficiency slope, 24 and heart rate recovery at 1 minute 25 have demonstrated prognostic value. Although these variables were unfortunately not available for the entire cohort in the present investigation, subgroup analysis revealed all 3 demonstrated significantly better characteristics in subjects who did not experience a major cardiac event. In addition, peak VO 2 adjusted for body fat has demonstrated prognostic value in patients with HF. 26, 27 Analysis of this expression of aerobic capacity could not be performed in the present study as body fat assessment was not performed in any of the subjects. Future research should be directed toward a more comprehensive multivariate survival analysis to determine all clinically relevant CPX variables and optimal expression.
In conclusion, variables obtained from CPX provide important prognostic insight in patients with HF. The findings of the present investigation further confirm the prognostic superiority of ventilatory efficiency (VE/VCO 2 slope) and suggest equations used to determine percent-predicted peak VO 2 provide similar and in some instances better predictive information compared with the measured value obtained from CPX. Although many laboratories conducting CPX in patients with HF report percent-predicted peak VO 2 values in their written report, they do not commonly consider its prognostic significance. Our results suggest that (1) peak VO 2 should be expressed as a percentage of the predicted normal value and this should be a routine part of the summary report, and (2) the Wasserman/Hansen equation is superior to other equations in terms of prognostic power in patients with HF.
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CLINICAL PERSPECTIVE
Previous investigations have consistently demonstrated that cardiopulmonary exercise testing is a valuable tool in the clinical and prognostic assessment of patients with heart failure. Peak oxygen consumption (VO 2 ) is one of the primary variables obtained from such testing and is typically assessed as an actual value relative to body weight. A number of prediction equations have been developed to estimate normal aerobic capacity and are readily available to clinicians. While documenting a percent-predicted peak VO 2 value on the cardiopulmonary exercise testing report is typically advocated, it is frequently not afforded any consideration by clinicians assessing prognosis or weighing treatment options based on the exercise response. The present study demonstrates that the percent-predicted peak VO 2 value derived from several established equations provide prognostic value in patients with heart failure. In particular, the prediction equation established by Wasserman and Hansen seems to provide optimal prognostic value, potentially outperforming the predictive resolution obtained from the actual peak VO 2 value. This study may provide healthcare professionals performing cardiopulmonary exercise testing with important information regarding which peak VO 2 prediction equation to use and its potential clinical value in patients with heart failure. In conclusion, clinicians responsible for the interpretation of cardiopulmonary exercise testing data in patients with heart failure should consider the clinical utility of all information that is gained from this valuable assessment technique.
